About

Pioneers in NETosis

Neutrolis is a clinical stage therapeutics company targeting Neutrophil Extracellular Traps (NETs) and other sources of pathologic extracellular DNA.

150 Years of Progress

The role of DNA as a key component of the human immune response has been observed for over 150 years. The specific mechanistic understanding of DNA’s involvement with disease, however, was a puzzle that took decades and significant scientific advancement to elucidate. With the discovery of NETs in 2004, it became clear that this fundamental and pathological source of extracellular DNA required improved therapeutic management.

Building on the precedent of previous DNASE therapies, which mainly targeted bacterial sources of DNA, Neutrolis is developing therapies that are capable of treating the scale and structure of extracellular DNA produced by NETosis. The company’s pipeline includes molecules generated by the exDNASETM platform that remove NETs and halt their pathologic effects.

1869
1959
1993
2004
2007
2010
2017
2021
1869
DNA first discovered in pus
1869
1959
1993
2004
2007
2010
2017
2021
1959
First lupus patient dosed with DNASE treatment
1869
1959
1993
2004
2007
2010
2017
2021
1993
Approval of Pulmozyme (rDNASE1)
1869
1959
1993
2004
2007
2010
2017
2021
2004
Discovery of NETs by Dr. Arturo Zychlinsky at the Max Planck Institute
1869
1959
1993
2004
2007
2010
2017
2021
2007
"NETosis" first described by Dr. Toby Fox
1869
1959
1993
2004
2007
2010
2017
2021
2010
NETs role in autoimmunity described by Dr. Abdul (Hakkim)
1869
1959
1993
2004
2007
2010
2017
2021
2017
Incorporation of Neutrolis
1869
1959
1993
2004
2007
2010
2017
2021
2021
First patient dosed with Neutrolis therapies

The Neutrolis Story

Neutrolis was founded in 2017 by Drs. Toby Fox and Abdul (Hakkim), two of the earliest and most-cited leaders in the NETs field. Toby and Hakkim have collaborated for over 18 years starting as molecular biologists in the lab of Dr. Arturo Zychlinsky at The Max Planck Institute for Infection Biology, who characterized NETs in a 2004 cover article in Science. After establishing careers in academia and industry, Toby and Hakkim cofounded Neutrolis to commercialize the innovative exDNASETM platform based on their unique understanding of NETs clearance mechanisms. Neutrolis is a clinical stage company developing a robust pipeline of therapeutics in major disease areas driven by NET-based pathologies starting with lupus.

Neutrolis Highlights

5+
years in operation 
17+
years of foundational
R&D in NETs 
$45M
raised to date
$33M
Series A in 2021
5
awards received from BMS, Pfizer and NIH

Founders

Toby Fox, PhD
Co-president, CEO & CSO

Toby Fox, PhD

Co-president, CEO & CSO

Toby is co-founder, CEO, CSO and co-president of Neutrolis. He is one of the most-cited researchers in the field of NETosis and the with important contributions towards the biology of NETs and its implications in vascular and ischemic injuries. Toby is a former principal investigator at University Medical Center in Hamburg-Eppendorf. He trained as an immunologist at Max Planck Institute and Harvard Medical School.

Abdul Hakkim, PhD
Co-president & COO

Abdul Hakkim, PhD

Co-president & COO

Hakkim is co-founder, COO and co-president of Neutolis. Hakkim and Toby were the first graduate students at the Max Planck to work on the biology and implications of NETs in autoimmunity. Hakkim is an immunologist trained at Max Planck Institute and Harvard Medical School. At Harvard, Hakkim worked on genetics of innate immunity before transitioning into an entrepreneur initially with Genma Biosciences, a therapeutics company spun out of Harvard University.

Expanded Management

Michael Fleming, MBA
CBSO

Michael Fleming, MBA

CBSO

Michael has 35+ years of experience in business development and commercialization within the biotech industry. Prior to joining Neutrolis, Michael held leadership roles at GSK, Genentech, Elan, Anacor, and Coherus BioSciences. At Neutrolis, he drives the company's growth and strategic direction, focusing on market analysis, strategic partnerships, and fundraising efforts. Michael leads cross-functional teams, ensures regulatory compliance, and fosters a culture of innovation, ensuring Neutrolis’ products align with market needs and achieve successful market entry.

Andreas Reiff, MD
CMO

Andreas Reiff, MD

CMO

Andreas has extensive experience in medical leadership, with a focus on advancing treatments for autoimmune and inflammatory diseases. Prior to joining Neutrolis, Andreas served as Rheumatology Division Head at Children's Hospital Los Angeles (CHLA), University of Southern California; as Senior VP (Immunology & Inflammation) at Parexel, and founded TheraKine Ltd. At Neutrolis, he oversees clinical development and medical strategy, to ensure the highest standards of medical ethics, safety and efficacy. Andreas guides the company through clinical trials, regulatory submissions, and medical affairs, dedicated to bringing transformative treatments to market.

Ralph Lambalot, PhD
CTO

Ralph Lambalot, PhD

CTO

Ralph has 25+ years of experience developing manufacturing processes and analytical methods in support of commercial, clinical and preclinical biotherapeutic products. Prior to joining Neutrolis, Ralph was VP of Biologics Operations Science & Technology at AbbVie overseeing development and commercial manufacturing of Humira® and previously held senior scientist roles at Pfizer and BASF. Ralph is a bioorganic chemist and trained at Brown University and Harvard Medical School. At Neutrolis, Ralph leads chemistry manufacturing and controls (CMC).

Ken Olivier Jr., PhD
EVP of Development

Ken Olivier Jr., PhD

EVP of Development

Ken has 22+ years of experience in drug development and regulatory strategy and is skilled in toxicology, regulatory affairs, and quality assurance. Ken is an experienced drug development veteran with a history of developing therapies in the biotechnology and pharmaceutical industry. Ken previously held positions in Regeneron, Biogen, GSK, and Merimak Pharmaceuticals. Ken received his Bachelors in Toxicology from the University of Louisiana at Monroe and PhD in Veterinary Biomedical and Clinical Sciences from Oklahoma State University. At Neutrolis, Ken oversees product development and assists with non-clinical and regulatory strategies.

Ghazaleh Gouya Lechner, MD
Head of Clinical Operations

Ghazaleh Gouya Lechner, MD

Head of Clinical Operations

Ghazaleh has 20+ years of clinical research experience and is an Associate Professor in Internal Medicine and board certified in internal medicine, cardiology, and clinical pharmacology. Previously, Ghazaleh lead a research group at the phase I Unite of the Medical University Vienna and was Medical Director at a global CRO. She has been involved in the development and approval of numerous products and has led product strategy and protocol development by identifying and documenting the best ways to help patients. Ghazaleh and her clinical team at Gouya Insights lead Neutrolis’ clinical strategy and operations.

‍

Board of Directors

Gerald Chan, SD

Gerald Chan, SD

Gerald is the cofounder of Morningside Group, an investment enterprise engaged in venture, private equity, and property investments. Working with academic scientists, he started over two dozen biotech companies across diverse therapeutic areas including oncology, inflammation, ophthalmology, autoimmunity, diabetes, neurodegeneration, rare genetic diseases, and prophylactic vaccines.

Gerald is a board member of several privately-held biotech companies. He is the chairman of two Nasdaq-listed biotechnology companies - Apellis Pharmaceuticals and Stealth BioTherapeutics. He is a trustee of the Scripps Research Institute in La Jolla, California, and a member of the Dean’s Board of Advisors of the Harvard T.H. Chan School of Public Health. He chairs the Advisory Committee of Emory University’s Innovative and Affordable Medicine, and is the past chair of the Innovation Advisory Committee of the Wellcome Trust, in London.

Gerald received his BS and MS degrees in engineering from UCLA, his Master’s degree in medical radiological physics, and a Doctor of Science degree in radiation biology from Harvard University. He received his post-doctoral training at the Dana-Farber Cancer Institute. He has been honored with six honorary degrees conferred by universities in the UK, Hong Kong, and America. In 2017, he was elected to membership in the American Academy of Arts and Sciences. In 2019, he gave the Andrew Carnegie Lecture at the University of Glasgow, Scotland, and held a fellowship at Trinity College, Cambridge University.

John Sundy, MD

John Sundy, MD

John brings extensive expertise in the clinical development of investigational therapies in immunology and inflammation. He is currently the Chief Medical Officer of Seismic Therapeutics and an Independent Board Member of Sanofi. Previously, he served as CMO at Pandion Therapeutics (acquired by Merck for $1.85B) and as Senior Vice President and inflammation therapeutic area head at Gilead Sciences. At Gilead, he led the company’s entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs including filgotinib, which was filed for marketing authorization globally in rheumatoid arthritis in 2019. Dr. Sundy was Associate Professor of Medicine at Duke University and the Duke-National University of Singapore Graduate Medical School. While at Duke he was instrumental in the clinical development of Krystexxa®, which was approved in 2010 for patients with refractory gout. He also served as Associate Director of the Duke Clinical Research Institute and Director of Duke's Global Proof of Concept Research Unit Network in the US, Singapore and India. Dr. Sundy received his B.S. in biology from Bucknell University and his M.D. and Ph.D. from Drexel University School of Medicine.

Anthony Aiudi, PharmD

Anthony Aiudi, PharmD

Anthony has been part of the investment team at Morningside Technology Advisory since 2020. He has experience providing operational and managerial oversight to early-stage biotechnology companies. Anthony serves on the boards of several biotechnology companies across a broad spectrum of therapeutic areas, including Fount Bio, Biothea, and Cyted. He has also facilitated company creation, completed multiple financings for private companies, and provided operational support for portfolio companies. Anthony completed a Fellowship in Clinical Research at Cubist Pharmaceuticals and Northeastern University, where he was also adjunct faculty. He later was a senior clinical research scientist at Merck & Co. From late 2015-2020, he was a director at Stealth BioTherapeutics, where he led the clinical development for numerous rare disease programs through their global Phase 3 program and supported the company through its IPO. Anthony received his Pharm.D. and MBA from the University of Rhode Island and an M.S. in finance from Northeastern University.

Toby Fox, PhD
Co-president, CEO & CSO

Toby Fox, PhD

Co-president, CEO & CSO

Toby is co-founder, CEO, CSO and co-president of Neutrolis. He is one of the most-cited researchers in the field of NETosis and the with important contributions towards the biology of NETs and its implications in vascular and ischemic injuries. Toby is a former principal investigator at University Medical Center in Hamburg-Eppendorf. He trained as an immunologist at Max Planck Institute and Harvard Medical School.

Abdul Hakkim, PhD
Co-president & COO

Abdul Hakkim, PhD

Co-president & COO

Hakkim is co-founder, COO and co-president of Neutolis. Hakkim and Toby were the first graduate students at the Max Planck to work on the biology and implications of NETs in autoimmunity. Hakkim is an immunologist trained at Max Planck Institute and Harvard Medical School. At Harvard, Hakkim worked on genetics of innate immunity before transitioning into an entrepreneur initially with Genma Biosciences, a therapeutics company spun out of Harvard University.

Scientific and Medical Advisory Board

Denisa Wagner, PhD
Senior Investigator, Program in Cellular and Molecular Medicine; Professor of Pediatrics, Harvard Medical School

Dr. Denisa Wager is a professor of medicine at Harvard Medical School, a senior investigator in the Program in Cellular and Molecular Medicine, and a member of the Division of Hematology/Oncology at Boston Children's Hospital.

Dr. Wagner is a key opinion leader in the field of NETs with #XXX publications in this space. She brings deep understanding of vascular biology, adhesion molecules and inflammatory pathways to Neutrolis and is a co-inventor on core aspects of Neutrolis’s proprietary technology.

Her research efforts have uncovered foundational aspects of how pathogenic NETs influence both acute and chronic disorders in humans.  These disorders include (thrombosis, atherosclerosis, reperfusion injury, wound healing, cancer associated thrombosis, stroke and ALI.

‍

Mark Looney, MD
Professor of Critical Care and Laboratory Medicine, Attending Physician on the Pulmonary Consult Service and the Intensive Care Units, University of California San Francisco.

Dr. Looney is a Professor of Medicine and Laboratory Medicine and Attending Physician on the Pulmonary Consult Service and the Intensive Care Units at UCSF. Dr. Looney advises Neutrolis on Acute Respiratory Distress Syndrome (ARDS) program and he is also the collaborator on the NIH-SBIR grant that Neutrolis received for developing therapies that target NETs in ARDS.

Dr. Looney is a key opinion leader in acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), primary graft dysfunction after lung transplantation, and cystic fibrosis.

Reinhard Voll, MD
Director of the Department of Rheumatology at the University of Freiburg

Dr. Voll is the Director of the Department of Rheumatology at the University of Freiburg and brings to Neutrolis extensive clinical expertise in autoimmune disorders and collaborates on identifying and validating biomarkers for lupus. Dr. Voll’s research focuses on apoptotic cell death in systemic Lupus erythematosus (SLE) and the treatment of antibody-mediated diseases.

‍

Karen Costenbader, MD, MPH
Professor of Rheumatology, Immunology and Allergy, Harvard Medical School; Director, Lupus program, Brigham and Women’s Hospital

Dr. Costenbader is the Director of the lupus program at Brigham and Women’s Hospital in Boston and Professor of Medicine at Harvard Medical School. She is also the Chair of the Medical-Scientific Advisory Council for Lupus Foundation of America. Dr. Costenbader advises Neutrolis on the clinical trial feasibility for lupus and is a collaborator on the NIH-SBIR grant that Neutrolis received to identify biomarkers for lupus therapy.

Dr. Costenbader as a key opinion leader for lupus and related autoimmune diseases.

‍

Kaplan J. Mariana., MD
Senior Investigator and Chief of Systemic Autoimmunity Branch at National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Dr. Kaplan is Senior Investigator and Chief of Systemic Autoimmunity Branch and Acting Director of Lupus Clinical Trial Unit at National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). She is a key opinion leader and her research focuses on identifying abnormalities of neutrophil subset and the role of NETs in lupus and rheumatoid arthritis and other systemic autoimmune disease. Dr. Kaplan advises Neutrolis on novel NET based lupus biomarkers and also clinical trial strategy for lupus and RA.

‍

Joseph A. Madri, PhD, MD
Professor of Pathology at Yale University School of Medicine

Dr. Madri is a Professor of Pathology at Yale University School of Medicine and founder of Alexion Pharmaceuticals Inc., a commercial-stage publicly traded ultra-rare orphan disease drug development company. Dr. Madri brings to Neutrolis extensive experience building a preeminent drug discovery and development organization from the earliest stages through launch of multiple commercial products. Dr. Madri also brings a deep understanding of the biological mechanism of inflammation and autoimmune disorders and serves on the editorial boards of numerous scientific journals.

Neutrolis, Inc.
1 Broadway
Cambridge, MA 02142

About
Platform
Pipeline
Patients
Contact
© 2024 Neutrolis | Terms of Use | Privacy Policy
Home
About
Platform
Pipeline
Patients
Contact